Westphalen C Benedikt, Kruger Stephan, Haas Michael, Heinemann Volker, Boeck Stefan
a Department of Internal Medicine III and Comprehensive Cancer Center , Klinikum Grosshadern, Ludwig-Maximilians-University of Munich , Munich , Germany.
Expert Opin Drug Saf. 2016 Jul;15(7):947-54. doi: 10.1080/14740338.2016.1177510. Epub 2016 May 3.
Pancreatic cancer is a major health burden. Currently, the majority of patients is diagnosed at advanced stages and thus qualifies for palliative chemotherapy. Gemcitabine monotherapy has been the gold standard for many years. Recently, more effective chemotherapeutic regimens have shown meaningful clinical activity in patients with metastatic pancreatic cancer.
In this review we have aimed to give an overview on the treatment options for patients diagnosed with metastatic pancreatic cancer with an emphasis on the safety and toxicity of the applied regimens. We have conducted a pubmed search using the terms 'metastatic pancreatic cancer', 'palliative chemotherapy', 'safety' and 'toxicity'. Our special focus rested on randomized phase III trials to provide readers with the highest level of available evidence.
The emergence of new and more effective chemotherapy regimens gives clinicians more freedom in the treatment of metastatic pancreatic cancer. While being more effective, these regiments have a considerable degree of toxicity. Choosing the right treatment for any individual will be the next major challenge treating patients with pancreatic cancer.
胰腺癌是一项重大的健康负担。目前，大多数患者在晚期才被诊断出来，因此适合接受姑息化疗。吉西他滨单药治疗多年来一直是金标准。最近，更有效的化疗方案在转移性胰腺癌患者中显示出有意义的临床活性。
在本综述中，我们旨在概述转移性胰腺癌患者的治疗选择，重点关注所用方案的安全性和毒性。我们使用“转移性胰腺癌”“姑息化疗”“安全性”和“毒性”等术语在PubMed上进行了检索。我们特别关注随机III期试验，以便为读者提供最高水平的现有证据。
新的和更有效的化疗方案的出现，使临床医生在治疗转移性胰腺癌时有了更多的选择自由。虽然这些方案更有效，但有相当程度的毒性。为每个患者选择合适的治疗方法将是治疗胰腺癌患者的下一个重大挑战。
